147 related articles for article (PubMed ID: 22182694)
21. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
23. Cytokine regulation of IL-12 receptor beta2 expression: differential effects on human T and NK cells.
Wu CY; Gadina M; Wang K; O'Shea J; Seder RA
Eur J Immunol; 2000 May; 30(5):1364-74. PubMed ID: 10820383
[TBL] [Abstract][Full Text] [Related]
24. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
25. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
28. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
[TBL] [Abstract][Full Text] [Related]
29. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
[TBL] [Abstract][Full Text] [Related]
30. Aberrant regulation of interleukin-12 receptor beta2 chain on type 1 cytokine-stimulated T lymphocytes in type 1 diabetes.
Skarsvik S; Ludvigsson J; Vaarala O
Immunology; 2005 Feb; 114(2):287-93. PubMed ID: 15667574
[TBL] [Abstract][Full Text] [Related]
31. Genomic effects of IFN-beta in multiple sclerosis patients.
Weinstock-Guttman B; Badgett D; Patrick K; Hartrich L; Santos R; Hall D; Baier M; Feichter J; Ramanathan M
J Immunol; 2003 Sep; 171(5):2694-702. PubMed ID: 12928423
[TBL] [Abstract][Full Text] [Related]
32. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS.
Zang YC; Yang D; Hong J; Tejada-Simon MV; Rivera VM; Zhang JZ
Neurology; 2000 Aug; 55(3):397-404. PubMed ID: 10932275
[TBL] [Abstract][Full Text] [Related]
33. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
34. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
35. Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier BC; Niederwieser G; Hartung HP; Archelos JJ
Neurology; 2002 Oct; 59(7):990-7. PubMed ID: 12370451
[TBL] [Abstract][Full Text] [Related]
36. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Soldan SS; Alvarez Retuerto AI; Sicotte NL; Voskuhl RR
J Immunol; 2003 Dec; 171(11):6267-74. PubMed ID: 14634144
[TBL] [Abstract][Full Text] [Related]
37. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
38. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
[TBL] [Abstract][Full Text] [Related]
40. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
